CYCLODEXTRIN IN NOVEL FORMULATIONS AND SOLUBILITY ENHANCEMENT TECHNIQUES: A REVIEW

SHRADDHA TODKAR; SHASHIKANT DHOLE; TANUJA UMATE; NILESH KULKARNI

doi:10.22159/ijcpr.2024v16i2.4032

Authors

SHRADDHA TODKAR Department of Pharmaceutics, PES Modern College of Pharmacy (For Ladies), Moshi, Pune, Affiliated to Savitribai Phule Pune University, Pune-412105, Maharashtra, India https://orcid.org/0009-0008-1579-8947
SHASHIKANT DHOLE Department of Pharmaceutics, PES Modern College of Pharmacy (For Ladies), Moshi, Pune, Affiliated to Savitribai Phule Pune University, Pune-412105, Maharashtra, India
TANUJA UMATE Department of Pharmaceutics, PES Modern College of Pharmacy (For Ladies), Moshi, Pune, Affiliated to Savitribai Phule Pune University, Pune-412105, Maharashtra, India https://orcid.org/0000-0002-4801-9419
NILESH KULKARNI Department of Pharmaceutics, PES Modern College of Pharmacy (For Ladies), Moshi, Pune, Affiliated to Savitribai Phule Pune University, Pune-412105, Maharashtra, India

DOI:

https://doi.org/10.22159/ijcpr.2024v16i2.4032

Keywords:

Cyclodextrin, Complexation, Inclusion complex, Solubility, Solubility Enhancement

Abstract

Using cyclodextrin helps make different dosage forms more soluble. The oligosaccharide class known as cyclodextrins (CDs) is made up of glucose units bound together in a ring. CDs have the promising ability to assemble into complexes with drug molecules and improve their physicochemical properties without the need for molecular modifications. Generally, drug-CD complexes have a stoichiometry of 1:1. However, natural CDs have a tendency to self-assemble and form aggregates in aqueous media, which can reduce the solubility of the CDs by aggregating. One can increase their complexation capacity and solubility through derivative formation, but the final outcome depends on the kind and extent of substitution. Drug penetration through biological membranes can be improved by the formation of water-soluble drug-CD complexes. Solubility is the property of a solid dissolving into a liquid phase to form a homogenous system. Solubility is a crucial component in obtaining the right drug concentration in the systemic circulation for the optimal pharmacological response. Orally administered poorly soluble drugs often require high dosages to reach therapeutic plasma concentrations. Their low solubility in water is one of the primary problems with creating new chemical entities through formulation. The BCS classification system places these medications in class II, which is characterized by high permeability and poor solubility. To greatly improve these medications, it is possible to make them more bioavailable and soluble.

Downloads

Download data is not yet available.

References

Ain S, Kumar B, Pathak K. Cyclodextrins: versatile carrier in drug formulations and delivery systems. Int J Pharm Chem Biol Sci. 2015 Jul 1;5(3):583-98.

Saokham P, Muankaew C, Jansook P, Loftsson T. Solubility of cyclodextrins and drug/cyclodextrin complexes. Molecules. 2018 May 11;23(5):1161. doi: 10.3390/molecules23051161, PMID 29751694.

Shimpi S, Chauhan B, Shimpi P. Cyclodextrins: application in different routes of drug administration. Acta Pharm. 2005 Jun 1;55(2):139-56. PMID 16179128.

Del Valle EMM. Cyclodextrins and their uses: a review. Process Biochem. 2004 May 31;39(9):1033-46. doi: 10.1016/S0032-9592(03)00258-9.

Muankaew C, Loftsson T. Cyclodextrin‐based formulations: a non‐invasive platform for targeted drug delivery. Basic Clin Pharmacol Toxicol. 2018 Jan;122(1):46-55. doi: 10.1111/bcpt.12917, PMID 29024354.

Jacob S, Nair AB. Cyclodextrin complexes: perspective from drug delivery and formulation. Drug Dev Res. 2018 Aug;79(5):201-17. doi: 10.1002/ddr.21452, PMID 30188584.

Thakur SS, Parekh HS, Schwable CH, Gan Y, Ouyang D. Solubilization of poorly soluble drugs: cyclodextrin‐based formulations. Comp Pharm. 2015 Jun 29:31-51.

Vyas A, Saraf S, Saraf S. Cyclodextrin based novel drug delivery systems. J Incl Phenom Macrocycl Chem. 2008 Oct;62(1-2):23-42. doi: 10.1007/s10847-008-9456-y.

Kim DH, Lee SE, Pyo YC, Tran P, Park JS. Solubility enhancement and application of cyclodextrins in local drug delivery. J Pharm Investig. 2020 Jan;50(1):17-27. doi: 10.1007/s40005-019-00434-2.

Gillet A, Grammenos A, Compère P, Evrard B, Piel G. Development of a new topical system: drug-in-cyclodextrin-in-deformable liposome. Int J Pharm. 2009 Oct 1;380(1-2):174-80. doi: 10.1016/j.ijpharm.2009.06.027, PMID 19576972.

Mura P, Bragagni M, Mennini N, Cirri M, Maestrelli F. Development of liposomal and microemulsion formulations for transdermal delivery of clonazepam: effect of randomly methylated β-cyclodextrin. Int J Pharm. 2014 Nov 20;475(1-2):306-14. doi: 10.1016/j.ijpharm.2014.08.066, PMID 25194352.

Nagarsenker MS, Amin L, Date AA. Potential of cyclodextrin complexation and liposomes in topical delivery of ketorolac: in vitro and in vivo evaluation. AAPS PharmSciTech. 2008 Dec;9(4):1165-70. doi: 10.1208/s12249-008-9157-2, PMID 19016331.

Maestrelli F, Gonzalez Rodriguez ML, Rabasco AM, Mura P. Preparation and characterisation of liposomes encapsulating ketoprofen–cyclodextrin complexes for transdermal drug delivery. Int J Pharm. 2005 Jul 14;298(1):55-67. doi: 10.1016/j.ijpharm.2005.03.033, PMID 15941634.

Jain SK, Gupta Y, Jain A, Amin S. Elastic liposomes bearing meloxicam-β-cyclodextrin for transdermal delivery. Curr Drug Deliv. 2008 Jul 1;5(3):207-14. doi: 10.2174/156720108784911677, PMID 18673264.

Vega E, Egea MA, Garduno Ramirez ML, Garcia ML, Sanchez E, Espina M. Flurbiprofen PLGA-PEG nanospheres: role of hydroxy-β-cyclodextrin on ex vivo human skin permeation and in vivo topical anti-inflammatory efficacy. Colloids Surf B Biointerfaces. 2013 Oct 1;110:339-46. doi: 10.1016/j.colsurfb.2013.04.045, PMID 23743255.

Skiba M, Skiba Lahiani M, Arnaud P. Design of nanocapsules based on novel fluorophilic cyclodextrin derivatives and their potential role in oxygen delivery. J Inclus Phenom Macrocyclic Chem. 2002 Dec;44(1/4):151-4. doi: 10.1023/A:1023090528809.

Varan C, Bilensoy E. Development of implantable hydroxypropyl-β-cyclodextrin coated polycaprolactone nanoparticles for the controlled delivery of docetaxel to solid tumors. J Incl Phenom Macrocycl Chem. 2014 Oct;80(1-2):9-15. doi: 10.1007/s10847-014-0422-6.

Lahiani Skiba M, Bounoure F, Shawky Tous S, Arnaud P, Skiba M. Optimization of entrapment of metronidazole in amphiphilic β-cyclodextrin nanospheres. J Pharm Biomed Anal. 2006 Jun 7;41(3):1017-21. doi: 10.1016/j.jpba.2006.01.021, PMID 16497467.

Nguyen TD. Synthesis and characterization of β-cyclodextrin/alginate nanoparticle as a novel drug delivery system. Chem Biochem Eng Q. 2015 Oct 14;29(3):429-35. doi: 10.15255/CABEQ.2014.2092.

Szente L, Puskas I, Sohajda T, Varga E, Vass P, Nagy ZK. Sulfobutylether-beta-cyclodextrin-enabled antiviral remdesivir: characterization of electrospun- and lyophilized formulations. Carbohydr Polym. 2021 Jul 15;264:118011. doi: 10.1016/j.carbpol.2021.118011, PMID 33910715.

Johannsdottir S, Jansook P, Stefansson E, Loftsson T. Development of a cyclodextrin-based aqueous cyclosporin a eye drop formulations. Int J Pharm. 2015 Sep 30;493(1-2):86-95. doi: 10.1016/j.ijpharm.2015.07.040, PMID 26220650.

Mognetti B, Barberis A, Marino S, Berta G, De Francia S, Trotta F. In vitro enhancement of the anticancer activity of paclitaxel by a cremophor-free cyclodextrin-based nanosponge formulation. J Incl Phenom Macrocycl Chem. 2012 Dec;74(1-4):201-10. doi: 10.1007/s10847-011-0101-9.

Ascenso A, Cruz M, Euleterio C, Carvalho FA, Santos NC, Marques HC. Novel tretinoin formulations: a drug-in-cyclodextrin-in-liposome approach. J Liposome Res. 2013 Sep 1;23(3):211-9. doi: 10.3109/08982104.2013.788026, PMID 23631723.

Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012;2012:195727. doi: 10.5402/2012/195727, PMID 22830056.

Jambhekar SS, Breen PJ. Drug dissolution: significance of physicochemical properties and physiological conditions. Drug Discov Today. 2013 Dec 1;18(23-24):1173-84. doi: 10.1016/j.drudis.2013.08.013, PMID 24042023.

Khatri H, Hussain MS, Tyagi S. Solubility enhancement techniques: an overview. World Journal of Pharmaceutical Research. 2022;11(05):468-82. doi: 10.20959/wjpr20225-23812.

Kim CK, Park JS. Solubility enhancers for oral drug delivery: can chemical structure manipulation be avoided? Am J Drug Deliv. 2004 Jun;2(2):113-30. doi: 10.2165/00137696-200402020-00004.

Patel BB, Patel JK, Chakraborty S, Shukla D. Revealing facts behind spray dried solid dispersion technology used for solubility enhancement. Saudi Pharm J. 2015 Sep 1;23(4):352-65. doi: 10.1016/j.jsps.2013.12.013, PMID 27134535.

Deshmukh AS, Tiwari KJ, Mahajan VR. Solubility enhancement techniques for poorly water-soluble drugs. PCI-Approved-IJPSN. 2017 May 31;10(3):3701-8. doi: 10.37285/ijpsn.2017.10.3.1.

Patel JN, Rathod DM, Patel NA, Modasiya MK. Techniques to improve the solubility of poorly soluble drugs. Int J Pharm Life Sci. 2012 Feb 1;3(2).

Singh J, Walia M, Harikumar SL. Solubility enhancement by solid dispersion method: a review. J Drug Delivery Ther. 2013 Sep 14;3(5):148-55. doi: 10.22270/jddt.v3i5.632.

Dhirendra K, Lewis S, Udupa N, Atin K. Solid dispersions: a review. Pak J Pharm Sci. 2009 Apr;22(2):234-46. PMID 19339238.